You have accessJournal of UrologyCME1 May 2022PD12-12 TUMOR ANTIGEN VACCINE ENHANCES ANTI-TUMOR EFFECTS OF IMMUNE CHECKPOINT INHIBITORS AGAINST REFRACTORY CANCERS Shohei Ueda, Miho Ushjima, Atsushi Irie, Yasuharu Nishimura, and Masatoshi Eto Shohei UedaShohei Ueda More articles by this author , Miho UshjimaMiho Ushjima More articles by this author , Atsushi IrieAtsushi Irie More articles by this author , Yasuharu NishimuraYasuharu Nishimura More articles by this author , and Masatoshi EtoMasatoshi Eto More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000002538.12AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Progressive and chemoresistant bladder cancer is problematic because of the poor prognosis. immune checkpoint blockade(ICB) have exhibited drastic anti-tumor efficacy in some patients, but the response rates is limited. Therefore, to improve efficacy of immunotherapy for refractory cancer, we have tried to develop a combination immunotherapy of tumor antigen vaccine and ICB in tumor-bearing mouse models. METHODS: We identified genes highly expressed in tumors but not in normal tissues by comparing RNA-seq data of mouse bladder cancer MB49, cisplatin-resistant MB49-CR, and lymphoma RMA cell lines, all of which are refractory to ICB, with datasets of 26 normal mouse tissues. Subsequently tumor-associated antigens-derived peptides predicted to have high binding affinities to MHC-I and -II molecules were identified by prediction algorithms. We also selected immunogenic and cancer-specific mutated Neo-antigenic peptides. MB49, MB49-CR, or RMA bearing mice were treated with these peptides vaccine and ICB. Finally, we investigated tumor infiltrating immune cells by flow cytometry, TCR repertoire analysis, and RNA-seq of inoculated tumors. RESULTS: In 50-80% of mice pre-immunized with these peptides, a growth of MB49 and RMA inoculated s.c. was prevented and those immunized mice rejected re-transplanted tumors. Furthermore, combination therapy of these peptide vaccines, and ICB synergistically inhibited tumor-growth of MB49-CR, MB49 and RMA indicating that the combination immunotherapy described above enhances therapeutic efficacy to treat refractory cancers. We also observed increases of tumor infiltrating CD8+ T cells expressing limited TCR-alpha and beta genes, and drastic changes of various types of tumor-infiltrating immune cells in tumor-bearing mice treated with the combination therapy. CONCLUSIONS: These results suggest that the combination immunotherapy described above enhances therapeutic efficacy to treat refractory cancer. Source of Funding: This work was supported by KAKENHI © 2022 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 207Issue Supplement 5May 2022Page: e199 Advertisement Copyright & Permissions© 2022 by American Urological Association Education and Research, Inc.MetricsAuthor Information Shohei Ueda More articles by this author Miho Ushjima More articles by this author Atsushi Irie More articles by this author Yasuharu Nishimura More articles by this author Masatoshi Eto More articles by this author Expand All Advertisement PDF DownloadLoading ...